Department of Cardiothoracic Surgery, Chongqing University Central Hospital, Chongqing 400014, P.R. China.
Oncol Rep. 2024 Oct;52(4). doi: 10.3892/or.2024.8786. Epub 2024 Aug 2.
Non‑small cell lung cancer (NSCLC) is a highly prevalent lung malignancy characterized by insidious onset, rapid progression and advanced stage at the time of diagnosis, making radical surgery impossible. Sirtuin (SIRT) is a histone deacetylase that relies on NAD+ for its function, regulating the aging process through modifications in protein activity and stability. It is intricately linked to various processes, including glycolipid metabolism, inflammation, lifespan regulation, tumor formation and stress response. An increasing number of studies indicate that SIRTs significantly contribute to the progression of NSCLC by regulating pathophysiological processes such as energy metabolism, autophagy and apoptosis in tumor cells through the deacetylation of histones or non‑histone proteins. The present review elaborates on the roles of different SIRTs and their mechanisms in NSCLC, while also summarizing novel therapeutic agents based on SIRTs. It aims to present new ideas and a theoretical basis for NSCLC treatment.
非小细胞肺癌(NSCLC)是一种高发的肺部恶性肿瘤,其特点为起病隐匿、进展迅速,且在诊断时已处于晚期,根治性手术无法实施。Sirtuin(SIRT)是一种依赖 NAD+发挥功能的组蛋白去乙酰化酶,通过调节蛋白质活性和稳定性来调控衰老过程。它与多种过程密切相关,包括糖脂代谢、炎症、寿命调节、肿瘤形成和应激反应。越来越多的研究表明,SIRTs 通过对肿瘤细胞中组蛋白或非组蛋白的去乙酰化作用,调节能量代谢、自噬和细胞凋亡等生理病理过程,从而显著促进 NSCLC 的进展。本综述详细阐述了不同 SIRTs 的作用及其在 NSCLC 中的机制,同时还总结了基于 SIRTs 的新型治疗药物。旨在为 NSCLC 的治疗提供新的思路和理论依据。